News

PipelineReview.com15h
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and ...
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...
PipelineReview.com15h
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
BOTHELL, WA, USA I August 05, 2025 I Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the presentation of favorable safety and tolerability data from a ...
PipelineReview.com15h
Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors
DONGGUAN, China I August 5, 2025 I Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the ...
PipelineReview.com15h
Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designation for EPI-321 in FSHD SOUTH SAN FRANCISCO, CA, USA I August 05, 2025 I Epicrispr Biotechnologies, a clinical-stage company ...
PipelineReview.com15h
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, The Netherlands; ZUG, Switzerland & GDAŃSK, Poland I August 05, 2025 I Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global ...
PipelineReview.com15h
Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1
OSLO, Norway I August 5, 2025 I Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced ...
PipelineReview.com1d
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
CARLSBAD, CA, USA I August 04, 2025 I Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel ...
PipelineReview.com1d
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
LONDON, UK I August 05, 2025 I Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today ...
PipelineReview.com1d
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – ...
PipelineReview.com1d
Ethris Doses First Patient in Phase 2a Clinical Trial of Lead mRNA Candidate ETH47 for Asthma
MUNICH, Germany I August 04, 2025 I Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today ...
PipelineReview.com1d
Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors
CAMBRIDGE, MA, USA I August 04, 2025 I Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics inspired by ...
PipelineReview.com1d
Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
SOUTH SAN FRANCISCO, CA, USA I August 04, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...